In conclusion, we demonstrate the clinical significance of SEMA4D in human AML by showing that SEMA4D/PlexinB1 promotes the progression of AML by activating the PI3K/Akt signaling pathway. Here, PLXNB1 is linked to acute myeloid leukemia.